scholarly journals GW26-e5383 Pioglitazone Decreases Plaque Thrombosis by Attenuating Plaque Inflammation. An In Vivo Study Using 18F-FDG PET/CT

2015 ◽  
Vol 66 (16) ◽  
pp. C94-C95
Author(s):  
Quanming Zhao ◽  
Mingduo Zhang ◽  
Xin Zhao ◽  
Tingting Feng
Keyword(s):  
Fdg Pet ◽  
In Vivo Study ◽  
Pet Ct ◽  
Plaque Inflammation ◽  
18F Fdg ◽  
Fdg Pet Ct

Abstract 35: DVT Inflammation Assessed by 18F-FDG-PET/CT Predicts Subsequent Vein Wall Scarring

2016 ◽  
Vol 36 (suppl_1) ◽  
Author(s):  
Chase W Kessinger ◽  
Ahmed Tawakol ◽  
Gregory R Wojtkiewicz ◽  
Peter K Henke ◽  
Ralph Weissleder ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Vena Cava ◽  
Standard Uptake Value ◽  
Vein Wall ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
The Right ◽  
Fdg Pet Ct

Objective: While venous thrombosis (VT)-induced inflammation facilitates thrombus resolution, inflammation causes vein wall scarring (VWS). Recently, statins have shown to improve VT resolution and reduce VT inflammatory components. In this study, we hypothesized that early VT inflammation detected by 18F-FDG positron emission tomography/computed tomography (PET/CT) could predict subsequent late stage VWS, and would be attenuated by statin therapy. Methods: Stasis VT was induced in 8-12 week old male C57BL/6 mice (n=31) in either the right jugular vein (n=13) or inferior vena cava (IVC,n=18). Animals in the IVC VT cohort were randomized to statin (n=8) or control (n=10) treatment. Statin, rosuvastatin (5mg/kg), was administered by oral gavage, daily starting 24 hours prior to VT induction; control mice received saline. All mice underwent survival FDG-PET/CT venography imaging on day 2. FDG inflammation signals (standard uptake value=SUV) were measured in the thrombosed vein and compared to the sham-operated venous segments or treatment control. On day 14, mice were sacrificed and VT tissue was resected. Picrosirius red staining allowed measurement of collagen and vein wall thickness in VT sections. Results: FDG-PET/CT at day 2 revealed increased inflammation signal activity in jugular VT (SUV 1.43 ± 0.3 VT vs. 0.81 ± 0.3 contralateral vein, p<0.0001). Statin-treated mice showed a trend of decreased inflammation signal at day 2 in the IVC VT models (SUV 1.02 ± 0.1 statin VT vs. 1.42 ± 0.2 control VT, p=0.07). Day 14 histological analysis revealed significantly reduced vein wall injury in statin-treated animals (thickness, 32±9.4 μm statin; vs. 56.2±14.7 μm control, p=0.02). Day 2 FDG-PET inflammation in VT correlated positively with the magnitude of day 14 VWS (jugular VT, Spearman r=0.62, p=0.02; IVC VT r=0.74, p<0.001, respectively). Conclusions: Quantitative FDG-PET/CT imaging demonstrates that early in vivo VT inflammation predicts subsequent VWS, a driver of post-thrombotic syndrome (PTS). The overall findings strengthen: (i) the link between inflammation and PTS; (ii) the translational potential of FDG-PET inflammation to predict VWS and PTS; and (iii) the concept that statins and other anti-inflammatory therapies could reduce VWS and PTS.

scholarly journals Variability in quantitative analysis of atherosclerotic plaque inflammation using 18F-FDG PET/CT

PLoS ONE ◽  
2017 ◽  
Vol 12 (8) ◽  
pp. e0181847 ◽  
Author(s):  
Karel-Jan D. F. Lensen ◽  
Alper M. van Sijl ◽  
Alexandre E. Voskuyl ◽  
Conny J. van der Laken ◽  
Martijn W. Heymans ◽  
...  
Keyword(s):  
Quantitative Analysis ◽  
Atherosclerotic Plaque ◽  
Fdg Pet ◽  
Pet Ct ◽  
Plaque Inflammation ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Skye Hsin-Hsien Yeh ◽  
Ming Hsien Lin ◽  
I. I. Leo Garcia Flores ◽  
Uday Mukhopadhyay ◽  
Danial Young ◽  
...  
Keyword(s):  
Histone Deacetylase ◽  
Fdg Pet ◽  
Ct Imaging ◽  
Cell Lung Carcinoma ◽  
Hdac Activity ◽  
Anticancer Effects ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Combining standard drugs with low doses of histone deacetylase inhibitors (HDACIs) is a promising strategy to increase the efficacy of chemotherapy. The ability of well-tolerated doses of HDACIs that act as chemosensitizers for platinum-based chemotherapeutics has recently been proven in many types and stages of cancer in vitro and in vivo. Detection of changes in HDAC activity/expression may provide important prognostic and predictive information and influence treatment decision-making. Use of [18F] FAHA, a HDAC IIa-specific radionuclide, for molecular imaging may enable longitudinal, noninvasive assessment of HDAC activity/expression in metastatic cancer. We evaluated the synergistic anticancer effects of cisplatin and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in xenograft models of nonsmall cell lung cancer (NSCLC) using [18F] FAHA and [18F] FDG PET/CT imaging. Cisplatin alone significantly increased [18F] FAHA accumulation and reduced [18F] FDG accumulation in H441 and PC14 xenografts; coadministration of cisplatin and SAHA resulted in the opposite effects. Immunochemical staining for acetyl-histone H3 confirmed the PET/CT imaging findings. Moreover, SAHA had a more significant effect on the acetylome in PC14 (EGFR exon 19 deletion mutation) xenografts than H441 (wild-type EGFR and KRAS codon 12 mutant) xenografts. In conclusion, [18F] FAHA enables quantitative visualization of HDAC activity/expression in vivo, thus, may represent a clinically useful, noninvasive tool for the management of patients who may benefit from synergistic anticancer therapy.

Delayed time-point 18F-FDG PET CT imaging enhances assessment of atherosclerotic plaque inflammation

2013 ◽  
Vol 34 (9) ◽  
pp. 860-867 ◽  
Author(s):  
Björn A. Blomberg ◽  
Scott R. Akers ◽  
Babak Saboury ◽  
Nehal N. Mehta ◽  
Gang Cheng ◽  
...  
Keyword(s):  
Atherosclerotic Plaque ◽  
Fdg Pet ◽  
Ct Imaging ◽  
Pet Ct ◽  
Plaque Inflammation ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Delayed Time ◽  
Time Point

scholarly journals In vivo confirmation of altered hepatic glucose metabolism in patients with liver fibrosis/cirrhosis by 18F-FDG PET/CT

2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Niklas Verloh ◽  
Ingo Einspieler ◽  
Kirsten Utpatel ◽  
Karin Menhart ◽  
Stefan Brunner ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Liver Fibrosis ◽  
Fdg Pet ◽  
Hepatic Glucose Metabolism ◽  
Pet Ct ◽  
Hepatic Glucose ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals Immune Response Visualized In Vivo by [18F]-FDG PET/CT after COVID-19 Vaccine

Diagnostics ◽  
2021 ◽  
Vol 11 (4) ◽  
pp. 676
Author(s):  
Romain-David Seban ◽  
Laurence Champion ◽  
Nicolas Deleval ◽  
Capucine Richard ◽  
Claire Provost
Keyword(s):  
Immune Response ◽  
Glucose Metabolism ◽  
Fdg Pet ◽  
Axillary Lymph ◽  
Imaging Features ◽  
Cell Immunity ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Worldwide deployment of COVID-19 vaccines is in progress. Recent immune activation following vaccination can sometimes be seen in fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography ([18F]-FDG PET/CT). As previously evidenced, FDG-avid axillary lymph node(s) are common in patients receiving vaccines against SARS-CoV-2, influenza virus, or human papillomavirus, and reflect a regional immune response. In addition, these findings may also be accompanied by an increased spleen glucose metabolism after the COVID-19 vaccine, which captures a systemic immune response. Hence, we provide here a clinical example demonstrating that immune response could be associated with increased glucose metabolism in lymphoid organs such as lymph nodes and the spleen, which are critical modulators of T cell immunity. We believe that it is of paramount importance that nuclear physicians should be able to recognize clinical and imaging features of such immune responses upon vaccination for COVID-19 and beyond.

Sign in / Sign up

Export Citation Format

Share Document